While the potential for major weight loss is high, the total amount an individual will lose varies on a case-by-case basis
In clinical trials, it has demonstrated significant weight loss effects, leading to its FDA approval for the following indication and usage: WEGOVY is a glucagon-like peptide-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: adult patients with an initial body mass index of 30 kg/m2 or greater or 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition
) Both have unique benefits and understanding how they work can help you choose the one that fits your health goals
Every patient gets a dedicated Patient Care Coordinator for questions, check-ins, and dose adjustments
Verified DEXA scan data from Highland Longevity patient
Share: A new study suggests that Wegovy, the popular weight loss drug, may carry a higher risk of a rare eye condition that can lead to sudden vision loss compared with other semaglutide medications